SCHEMBL21836697

SCHEMBL21836697

CCOC(=O)c1c2c(nn1CC)CCCC2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.46
POLB P06746 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
LMNA P02545 3/20 0.42
KDM4E B2RXH2 5/20 0.41
ACHE P22303 4/20 0.41
HPGD P15428 4/20 0.40
ALDH1A1 P00352 3/20 0.40
HSD17B10 Q99714 3/20 0.40
ALOX15 P16050 2/20 0.40
GAA P10253 1/20 0.40
MAPK1 P28482 1/20 0.40
KMT2A Q03164 2/20 0.39
ADRA2A P08913 1/20 0.39
ADRA2B P18089 1/20 0.39
ADRA2C P18825 1/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26690229 0.97 MAPT (0.43) MAPTPOLBTDP1L3MBTL1LMNA
SCHEMBL3795546 0.82 POLB (0.58) MAPTPOLBTDP1L3MBTL1LMNA
SCHEMBL182200 0.82 MAPK1 (0.52) MAPTPOLBTDP1LMNAKDM4E
SCHEMBL17024846 0.82 TRPM2 (0.39) MAPTPOLBTDP1L3MBTL1LMNA
SCHEMBL24289267 0.80 ALDH1A1 (0.37) MAPTPOLBKDM4EHPGDALDH1A1
SCHEMBL9149378 0.80 ACHE (0.46) MAPTPOLBLMNAKDM4EACHE
SCHEMBL21836678 0.80 POLB (0.50) MAPTPOLBTDP1L3MBTL1LMNA
SCHEMBL9955982 0.80 POLB (0.50) MAPTPOLBTDP1L3MBTL1LMNA
SCHEMBL2719811 0.78 ALDH1A1 (0.42) MAPTPOLBTDP1L3MBTL1LMNA
SCHEMBL28542835 0.78 ALDH1A1 (0.36) MAPTPOLBKDM4EHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11597725-B2 URAT1 inhibitor for promoting uric acid excretion JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2023-03-07 US disclosed
EP-3632904-B1 URAT1 INHIBITORS FOR PROMOTING URIC ACID EXCRETION JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2022-04-20 EP disclosed
EP-3632904-B1 URAT1 INHIBITORS FOR PROMOTING URIC ACID EXCRETION JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2022-04-20 EP disclosed
US-20200262832-A1 URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2020-08-20 US disclosed
EP-3632904-A1 URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. (CN) 2020-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11597725-B2 URAT1 inhibitor for promoting uric acid excretion SLC10A6, SLC10A1, SLC28A1 MAPT 798/4885POLB 3944/4885TDP1 851/4885
US-20200262832-A1 URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION SLC10A6, SLC10A1, SLC28A1 MAPT 798/4885POLB 3944/4885TDP1 851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.